Alkermes plc (NASDAQ:ALKS) Director David W. Anstice sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, June 7th. The shares were sold at an average price of $24.00, for a total transaction of $120,000.00. Following the sale, the director now owns 78,081 shares in the company, valued at $1,873,944. The sale was disclosed in a filing with the SEC, which is available at this link.
Alkermes stock opened at $25.15 on Friday. The business’s 50 day moving average price is $21.60. The company has a market cap of $4.04 billion, a price-to-earnings ratio of -41.92 and a beta of 0.98. Alkermes plc has a 1-year low of $15.35 and a 1-year high of $25.30. The company has a quick ratio of 2.38, a current ratio of 2.75 and a debt-to-equity ratio of 0.28.
Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Tuesday, April 27th. The company reported $0.11 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.13. The firm had revenue of $251.43 million for the quarter, compared to analyst estimates of $233.78 million. Alkermes had a negative net margin of 9.06% and a negative return on equity of 0.15%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.01 EPS. As a group, research analysts anticipate that Alkermes plc will post -0.09 earnings per share for the current year.
ALKS has been the topic of a number of recent research reports. Mizuho restated a “buy” rating and set a $29.00 price target on shares of Alkermes in a research note on Tuesday, June 1st. HC Wainwright upped their target price on shares of Alkermes from $24.00 to $25.00 and gave the stock a “neutral” rating in a report on Wednesday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $22.20.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
Further Reading: What is Blockchain?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.